A statistical analysis of in vitro human microsomal metabolic stability of small phenyl group substituents, leading to improved design sets for parallel SAR exploration of a chemical series

Bioorganic and Medicinal Chemistry

Volumn 18, Issue 12, 2010, Pages 4405-4414

  Dossetter, Alexander G ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

ADMET; In vitro clearance; In vitro HLM stability; Matched molecular pairs

Indexed keywords

PHENYL GROUP; BENZENE DERIVATIVE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYCLIN DEPENDENT KINASE 2; PROTEIN KINASE INHIBITOR;

ARTICLE; CELL METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; STATISTICAL ANALYSIS; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG DESIGN; FACTUAL DATABASE; METABOLISM; STATISTICAL MODEL; STRUCTURE ACTIVITY RELATION;

BENZENE DERIVATIVES; CYCLIN-DEPENDENT KINASE 2; DATABASES, FACTUAL; DRUG DESIGN; HUMANS; MICROSOMES, LIVER; MODELS, STATISTICAL; PROTEIN KINASE INHIBITORS; RECEPTORS, CCR5; STRUCTURE-ACTIVITY RELATIONSHIP; CCR5 RECEPTOR ANTAGONISTS;

EID: 77953137063     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2010.04.077     Document Type: Article

References (57)

1. Topliss J.G. J. Med. Chem. 15 (1972) 1006
2. Leeson P.D., and Springthorpe B. Nat. Rev. Drug Disc. 6 (2007) 881
3. Barnhart T. J. Compet. Lean Think Future State spring (2008) 1
4. Russell K. Pharma Focus Asia 7 (2008) 48
5. Andersson S., Armstrong A., Bjore A., Bowker S., Chapman S., Davies R., Donald C., Egner B., Elebring T., Holmqvist S., Inghardt T., Johannesson P., Johansson M., Johnstone C., Kemmitt P., Kihlberg J., Korsgren P., Lemurell M., Moore J., Pettersson J.A., Pointon H., Ponten F., Schofield P., Selmi N., and Whittamore P. Drug Discovery Today 14 (2009) 598
6. Hammond C., and O'Donnell C.J. Drug Discovery World spring (2008) 9
7. 3, 303K) δ 0.85-1.00 (m, 2H); 1.11 ('q', 2H); 1.39 ('hp', 2H); 2.31 (q, 1H); 3.26 (dd, 2H); 3.30 (q, 1H); 4.50 (s, 2H); 6.27 (d, 1H); 6.64 (d, 1H); 6.75-6.85 (m, 5H).
8. Scientists at Berlex laboratories also discovered a similar chemical series, and similar SAR:. Wei R.G., Arnaiz D.O., Chou Y.-L., Davey D., Dunning L., Lee W., Lu S.-F., Onuffer J., Ye B., and Phillips G. Bioorg. Med. Chem. Lett. 17 (2007) 231
9. Hajduk P.J., and Sauer D.R. J. Med. Chem. 51 (2008) 553
10. Lewis M.L., and Cucurull-Sanchez L. J. Comput. Aided Mol. Des. 23 (2009) 97
11. -1 gradient: 5-95% A over 7 min, held at 95% for 1.5 min.
12. For data analysis methods used at AstraZeneca (PLC) and a similar process examining physiochemical processes see:. Leach A.G., Jones H.D., Cosgrove D.A., Kenny P.W., Ruston L., MacFaul P., Wood J.M., Colclough N., and Law B. J. Med. Chem. 49 (2006) 6672
13. The MDL Drug Data Report, available from Symyx Technologies. http://www.symyx.com/products/databases/bioactivity/mddr/index.jsp (accessed and searched Dec 1st 2008).
14. Sheridan R.P. J. Chem. Inf. Comput. Sci. 42 (2002) 103
15. For a recent review of the role of fluorine in the metabolism of Drug molecules see:. Park K.B., Kitteringham N.R., and O'Neill P.M. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 443
16. For a discussion of the role of fluorine in medicinal chemistry see:. Hagmann W.K. J. Med. Chem. 51 (2008) 4359
17. Coon M.J., Vaz A.D.N., McGinnity D.F., and Peng H.-M. Drug Metab. Dispos. 26 (1998) 1190
18. Guengerich F.P., and MacDonald T.L. FASEB 4 (1990) 2453
19. Wade R.C. J. Comput. Aided. Mol. Des. 4 (1990) 199
20. Guengerich F.P., Yun C.-H., and MacDonald T.L. J. Biol. Chem. 271 (1996) 27321
21. Smith D.A., Ackland M.J., and Jones B.C. Drug Discovery Today 2 (1997) 406
22. Smith D.A., Ackland M.J., and Jones B.C. Drug Discovery Today 2 (1997) 479
23. Smith D.A., Jones B.C., and Walker D.K. Med. Res. Rev. 16 (1996) 243
24. Koerts J., Soffers A.E.M.F., Vervoort J., De Jager A., and Rietjens I.M.C. Chem. Res. Toxicol. 11 (1998) 503
25. Dear G.J., Ismail I.M., Mutch P.J., Plumb R.S., and Davies L.H. Xenobiotica 30 (2000) 407
26. Cnubben N.H.P., Peelen S., Borst J.W., Vervoort J., and Veeger C. Chem. Res. Toxicol. 7 (1994) 590
27. Smith D.A., and Jones B.C. Biochem. Pharmacol. 44 (1992) 2089
28. Applequist D.E., and Klug J.H. J. Org. Chem. 43 (1978) 1729
29. Ferguson K.C., and Whittle E. Trans. Faraday Soc. 67 (1971) 2618
30. Chauret N., Guay D., Li C., Day S., Silva J., Blouin M., Ducharme Y., Yergey J.A., and Nicoll-Griffith D.A. Bioorg. Med. Chem. Lett. 12 (2002) 2149
31. Additional heterocycle isosteres have been studied and these results will be published in due course.
32. For an example of N-oxidation of pyridine with a drug compound see:. Bu H.-Z. Drug Metab. Dispos. 34 (2006) 1798
33. Hansch C., Leo A., and Hoekmann D. J. Am. Chem. Soc. 2 (1995)
34. Kubinyi H. Quant. Struct.-Act. Relat. 7 (1988) 121
35. Lewis D.F.V., and Dickins M. Toxicology 170 (2003) 45
36. Lewis D.F.V., and Dickins M. Drug Discovery Today 7 (2002) 918
37. Lewis D.F.V., and Lake B.G. Toxicology 125 (1998) 31
38. For QSAR and enzyme research on P450 3A4 specific:. Szklarz G.D., and Halpert J.R. J. Comput. Aided. Mol. Des. 11 (1997) 265
39. Donamski T.L., Liu J., Harlow G.R., and Halpert J.R. Arch. Biochem. Biophys. 350 (1998) 223
40. Ekins S., Bravi G., Wikel J.H., and Wrighton S.A. J. Pharmacol. Exp. Therap. 291 (1999) 424
41. Harlow G.R., and Halpert J.R. J. Biol. Chem. 272 (1997) 5396
42. He Y.A., He Y.Q., Szklarz G.D., and Halpert J.R. Biochemistry 36 (1997) 8831
43. Afzelius L., Zamora I., Ridderstrom M., Andersson T.B., Karlen A., and Masimirembwa C.M. Mol. Pharm. 59 (2001) 909
44. Lewis D.F.V. Xenobiotica 32 (2002) 305
45. Gleeson P., Bravi G., Modi S., and Lowe D. Bioorg. Med. Chem. Lett. 17 (2009) 5906
46. Burrows J.N., Cumming J.G., Fillery S.M., Hamlin G.A., Hudson J.A., Jackson R.J., McLaughlin S., and Shaw J.S. Bioorg. Med. Chem. Lett. 15 (2005) 25
47. Cumming J.G., Cooper A.E., Grime K., Logan C.J., McLaughlin S., Oldfield J., Shaw J.S., Tucker H., Winter J., and Whittaker D. Bioorg. Med. Chem. Lett. 15 (2005) 5012
48. Cumming J.G., Brown S., Cooper A.E., Faull A., Flynn A., Grime K., Oldfield J., Shaw J.S., Shepard E., Tucker H., and Whittaker D. Bioorg. Med. Chem. Lett. 16 (2006) 3533
49. Anderson M., Andrews D.A., Barker A.J., Brassington C.A., Breed J., Byth K.F., Culshaw J.D., Finlay M.R.V., Fisher E., McMiken H.H.J., Green C.P., Heaton D.W., Nash I.A., Newcombe N.J., Oakes S.E., Paupit R.A., Roberts A., Stanway J.J., Thomas A.P., Tucker J.A., Walker M., and Weir H.M. Bioorg. Med. Chem. Lett. 18 (2008) 5487
50. Barton, P. J.; Jewesbury, P. J.; Pease, J. E. WO 2004/033427.
51. Blomberg N., Cosgrove D.A., Kenny P.W., and Kolmodin K. J. Comput. Aided Des. 23 (2009) 513
52. For recent comparison of similarity methods and references within see:. Haranczyk M., and Holliday J. J. Chem. Inf. Model. 48 (2008) 498
53. Patterson D.E., Cramer R.D., Ferguson A.M., Clark R.D., and Weinberger L.E. J. Med. Chem. 9 (1996) 3049
54. Dunnett C.W., and Crisafior J. J. Pharm. Pharmacol. 7 (1955) 314
55. Dunnett C.W. J. Am. Stat. Ass. 50 (1955) 1096
56. Tukey, 1953, unpublished proposal: Kramer, C.Y. Biometics, 1956, 12, 307.
57. 10 unit was not populated enough, and more likely to be error prone, and as low as twofold was too close to experimental error of the assay.